Cardiol Therapeutics
Oakville
About Cardiol Therapeutics
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $97.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: tsx:CRDL
- Website: cardiolrx.com
- Phone: 289.910.0850
Industries & Categories
Biotechnology, Life Science, Nanotechnology
Social Profiles
Canonical: https://fsome.com/organization/cardiol-therapeutics-122280 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.